TerminatedNCT00665444

Study of Aripiprazole to Reduce Medical Risks in Bipolarity

Medication studyAges 18–65United States

The study in practice

Understand this study

This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

The study group receives aripiprazole as a study medication.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateApril 2008

Recruitment status: Terminated
Enrollment listed in the registry: 3
Sponsor: University of Pittsburgh
Sponsor type: University
Study type: Drug
Intervention type: Drug
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT00665444
Official title: Show the full official title
Reducing Medical Risks in Individuals With Bipolar Disorder: Enhancing Outcomes With Aripiprazole

Terminated

Pittsburgh

FAQ

Who is behind this study?

The study sponsor is University of Pittsburgh, a university.

Does this study involve medication?

Yes. The study involves medication, including Aripiprazole.

Who can participate?

This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.